A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part I: Clinical aspects.

The optimal schedule for recombinant interleukin-2 (rIL-2) administration is unclear. Because the clinical and immunological effects of prolonged continuous exposure to rIL-2 are unknown, we have conducted a phase I study to assess the toxicity and feasibility of continuous low dose infusion of rIL-...

Descripción completa

Detalles Bibliográficos
Autores principales: Vlasveld, L. T., Rankin, E. M., Hekman, A., Rodenhuis, S., Beijnen, J. H., Hilton, A. M., Dubbelman, A. C., Vyth-Dreese, F. A., Melief, C. J.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1992
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977401/
https://www.ncbi.nlm.nih.gov/pubmed/1586602

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977401/
https://www.ncbi.nlm.nih.gov/pubmed/1586602

Ejemplares similares